🇺🇸 G-CSF (Filgrastim) in United States

590 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutropenia — 92 reports (15.59%)
  2. Pyrexia — 88 reports (14.92%)
  3. Febrile Neutropenia — 76 reports (12.88%)
  4. Hypotension — 56 reports (9.49%)
  5. Nausea — 55 reports (9.32%)
  6. Diarrhoea — 50 reports (8.47%)
  7. Vomiting — 47 reports (7.97%)
  8. Platelet Count Decreased — 44 reports (7.46%)
  9. Haemoglobin Decreased — 43 reports (7.29%)
  10. Mucosal Inflammation — 39 reports (6.61%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is G-CSF (Filgrastim) approved in United States?

G-CSF (Filgrastim) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for G-CSF (Filgrastim) in United States?

M.D. Anderson Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.